Drug Insights

Using Synapse for Your Tamsulosin Research: An Easy Guide

6 February 2024
2 min read

Tamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a kidney stone is better when the stone is larger. It is taken by mouth. Common side effects include dizziness, headache, sleeplessness, nausea, blurry vision, and sexual problems. Other side effects may include feeling lightheaded with standing and angioedema. Tamsulosin is an alpha blocker and works by relaxing muscles in the prostate. Click on the image below to begin the exploration journey of Tamsulosin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Sarepta Therapeutics' SRP-5051 Shows Promise in MOMENTUM Phase 2 Trial for Duchenne Muscular Dystrophy
Latest Hotspot
3 min read
Sarepta Therapeutics' SRP-5051 Shows Promise in MOMENTUM Phase 2 Trial for Duchenne Muscular Dystrophy
6 February 2024
Sarepta Therapeutics Reveals Encouraging Results from Segment B in the MOMENTUM Phase 2 Trial for SRP-5051, Targeting Exon 51 Skip-Amenable Duchenne Muscular Dystrophy Cases.
Read →
Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach
Drug Insights
2 min read
Accessing Methocarbamol Information on Synapse: A Step-by-Step Approach
6 February 2024
Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain.
Read →
U.S. FDA Clears Takeda's GAMMAGARD LIQUID® for Chronic Inflammatory Nerve Disorder Treatment in Adults
Latest Hotspot
4 min read
U.S. FDA Clears Takeda's GAMMAGARD LIQUID® for Chronic Inflammatory Nerve Disorder Treatment in Adults
6 February 2024
Takeda has disclosed that GAMMAGARD LIQUID®, their intravenous immunoglobulin treatment, has received authorization from the U.S. Food and Drug Administration.
Read →
Maximize Your Synapse Use: Your Guide to Searching Clindamycin
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Clindamycin
6 February 2024
Clindamycin was first made in 1966 from lincomycin and it is of the lincosamide class and works by blocking bacteria from making protein.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.